Catching Leaks on the Fly - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catching Leaks on the Fly
As drug sensitivity increases, on-line testing is likely to become more widespread and enable detection of defective blister cards.


Pharmaceutical Technology


For sensitive, expensive drugs, however, the expense could be justifiable. At least one other alternative is available to drug makers not quite ready to make that investment: surface inspection of the formable web before filling and sealing. This imaging-based system potentially could eliminate some leakers by detecting visually imperceptible cracks, pinholes, and other defects as small as 10 μm at 3.75 m/s. Especially suitable for foil, the unit also can check nontransparent film and laminated paper. Multiple zone inspection prevents rejection of good blisters ("VisioScan," inspection system Uhlmann VisioTec, Towaco, NJ, http://www.uhlmann-visiotec.com/).

Meanwhile, when implementing a leak-testing program, quality specifications for incoming materials must be considered. When looking at in-house quality control, a product's sensitivity and cost will determine whether leak testing is needed, whether it's off- or on-line, and how sensitive the equipment must be. Although it may technically be possible to locate defects measuring just a few micrometers, it's only necessary to do so if a hole that size will affect the product negatively. Other considerations in equipment selection include data-collection and networking capabilities, ease of calibration and validation, material limitations, tooling costs, cycle time, and changeover.

Hallie Forcinio is Pharmaceutical Technology's Packaging Forum editor, 4708 Morningside Drive, Cleveland, OH 44109, tel. 216.351.5824, fax 216.351.5684,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here